Clinical trials · Washington, D.C., DC
Alzheimer’s disease clinical trials in Washington, D.C.
We’re tracking 29 recruiting alzheimer’s disease studies with a site in or near Washington, D.C. — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05010603Recruiting
Studies families to understand late-onset Alzheimer’s
This study focuses on people with late-onset Alzheimer’s (and some similar memory diseases) and uses a close family “informant” to share what they’ve noticed. It may help researchers learn more about these conditions and how they progress in families.
Washington D.C., District of ColumbiaAges 55 years+ - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Washington D.C., District of ColumbiaAges 60–85 - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Washington D.C., District of ColumbiaAges 55–90 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Washington D.C., District of ColumbiaAges 55–90 - NCT05704309Enrolling by invitation
Study of diabetes prevention participants using brain scans
This study looks at how people who previously took part in a diabetes prevention program are doing over time, including brain health using MRI scans for some participants. It may help researchers understand who is at higher risk for memory and thinking problems and why.
Washington D.C., District of ColumbiaAges Any age - NCT03702907Recruiting
Study of aging and a brain sample bank
This study follows adults as they age and may collect biological samples for future research. It could help researchers understand early and late changes related to aging and brain health.
Washington D.C., District of ColumbiaAges 45 years+ - NCT05139290Enrolling by invitation
Support for African American families managing dementia care decisions
This study focuses on helping African American people with mild to moderate dementia and their family caregivers make better care decisions together. It also includes people who help with navigating healthcare when dementia care becomes harder.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Washington D.C., District of ColumbiaAges 55–80 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Arlington, VirginiaAges 55–90 - NCT07170150RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Arlington, VirginiaAges 50–90 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Arlington, VirginiaAges 50–90 - NCT07169630RecruitingPhase 1
PET scan study for Alzheimer's or mild cognitive impairment
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
Bethesda, MarylandAges 50–100 - NCT04396873RecruitingPhase 1
PET brain scan study of inflammation markers in neurodegeneration
This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.
Bethesda, MarylandAges 18–99 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Vienna, VirginiaAges 55–90 - NCT05543681RecruitingPhase 2
Study drug for agitation in Alzheimer’s dementia with caregiver support
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Clinton, MarylandAges 60 years+ - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Fairfax, VirginiaAges 55–80 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Fairfax, VirginiaAges 50–85 - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Fairfax, VirginiaAges 50–92 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Gaithersburg, MarylandAges 55–90 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Gaithersburg, MarylandAges 55–90 - NCT07611396Recruiting
Study of brain changes in memory and thinking with aging
This study follows people with normal thinking, early memory problems, or Alzheimer's disease to understand how the brain changes over time. Researchers will use smell tests, blood work, and memory testing to learn more about these conditions and potentially help future treatments.
Germantown, MarylandAges 55 years+ - NCT05282550RecruitingPhase 2
Trazodone trial to improve sleep in early Alzheimer’s
This study tests whether the sleep medicine trazodone can improve thinking and memory in people with early Alzheimer’s-related changes who also have sleep problems. If better sleep helps the brain, it may improve memory test results over time.
Baltimore, MarylandAges 55 years+ - NCT05795634Recruiting
Study stress effects in people at risk for Alzheimer’s
This study looks at how stress may affect thinking and memory in people with mild cognitive impairment (MCI) who are at risk for Alzheimer’s disease. You may be asked to do thinking tests and also involve a knowledgeable person who can report on changes over time.
Baltimore, MarylandAges 60 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age
Hear when a new Alzheimer’s disease trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Alzheimer’s disease trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Georgetown University Medical Center · 5 studies
- Johns Hopkins University · 4 studies
- Re:Cognition Health · 3 studies
- Howard University Hospital · 2 studies
- Local Institution · 2 studies
- National Institutes of Health Clinical Center · 2 studies
- Sana Research, LLC · 2 studies
- Biostatistics Center, George Washington University
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting alzheimer’s disease studies in District of Columbia.
Common questions
- Are there alzheimer’s disease clinical trials near Washington, D.C.?
- Yes. We're currently tracking 29 recruiting alzheimer’s disease studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.